These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
355 related articles for article (PubMed ID: 11196194)
21. Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas. Foca C; Moses EK; Quinn MA; Rice GE Gynecol Oncol; 2000 Nov; 79(2):244-50. PubMed ID: 11063652 [TBL] [Abstract][Full Text] [Related]
22. Posttranscriptional regulation of urokinase receptor expression by heterogeneous nuclear ribonuclear protein C. Velusamy T; Shetty P; Bhandary YP; Liu MC; Shetty S Biochemistry; 2008 Jun; 47(24):6508-17. PubMed ID: 18494499 [TBL] [Abstract][Full Text] [Related]
23. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity. Stillfried GE; Saunders DN; Ranson M Breast Cancer Res; 2007; 9(1):R14. PubMed ID: 17257442 [TBL] [Abstract][Full Text] [Related]
24. Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma. Bhuvarahamurthy V; Schroeder J; Kristiansen G; Roigas J; Denkert C; Johannsen M; Lein M; Loening SA; Schnorr D; Jung K; Staack A Oncol Rep; 2005 Sep; 14(3):777-82. PubMed ID: 16077991 [TBL] [Abstract][Full Text] [Related]
25. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator. Mahanivong C; Yu J; Huang S Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542 [TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma. Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307 [TBL] [Abstract][Full Text] [Related]
27. A urokinase receptor mRNA binding protein-mRNA interaction regulates receptor expression and function in human pleural mesothelioma cells. Shetty S; Idell S Arch Biochem Biophys; 1998 Aug; 356(2):265-79. PubMed ID: 9705217 [TBL] [Abstract][Full Text] [Related]
28. The effect of thrombospondin-1 and TGF-beta 1 on pancreatic cancer cell invasion. Albo D; Berger DH; Tuszynski GP J Surg Res; 1998 Apr; 76(1):86-90. PubMed ID: 9695745 [TBL] [Abstract][Full Text] [Related]
29. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Tuck AB; Arsenault DM; O'Malley FP; Hota C; Ling MC; Wilson SM; Chambers AF Oncogene; 1999 Jul; 18(29):4237-46. PubMed ID: 10435636 [TBL] [Abstract][Full Text] [Related]
30. Expression and function of the urokinase type plasminogen activator during mouse hemochorial placental development. Teesalu T; Blasi F; Talarico D Dev Dyn; 1998 Sep; 213(1):27-38. PubMed ID: 9733098 [TBL] [Abstract][Full Text] [Related]
31. Thrombospondin-1 up-regulates tumor cell invasion through the urokinase plasminogen activator receptor in head and neck cancer cells. Albo D; Tuszynski GP J Surg Res; 2004 Jul; 120(1):21-6. PubMed ID: 15172186 [TBL] [Abstract][Full Text] [Related]
33. Urokinase plasminogen activator amino-terminal peptides inhibit development of the rat ventral prostate. Elfman F; Bok R; Conn M; Shuman M; Cunha G Differentiation; 2001 Dec; 69(2-3):108-20. PubMed ID: 11798065 [TBL] [Abstract][Full Text] [Related]
34. In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor. Mohanam S; Chintala SK; Go Y; Bhattacharya A; Venkaiah B; Boyd D; Gokaslan ZL; Sawaya R; Rao JS Oncogene; 1997 Mar; 14(11):1351-9. PubMed ID: 9178895 [TBL] [Abstract][Full Text] [Related]
35. Requirement of TGF-beta receptor-dependent activation of c-Jun N-terminal kinases (JNKs)/stress-activated protein kinases (Sapks) for TGF-beta up-regulation of the urokinase-type plasminogen activator receptor. Yue J; Sun B; Liu G; Mulder KM J Cell Physiol; 2004 May; 199(2):284-92. PubMed ID: 15040011 [TBL] [Abstract][Full Text] [Related]
36. Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies. Carriero MV; Franco P; Del Vecchio S; Massa O; Botti G; D'Aiuto G; Stoppelli MP; Salvatore M Cancer Res; 1994 Oct; 54(20):5445-54. PubMed ID: 7923178 [TBL] [Abstract][Full Text] [Related]
37. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder. Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521 [TBL] [Abstract][Full Text] [Related]
38. Overexpression of urokinase receptor increases matrix invasion without altering cell migration in a human osteosarcoma cell line. Karikó K; Kuo A; Boyd D; Okada SS; Cines DB; Barnathan ES Cancer Res; 1993 Jul; 53(13):3109-17. PubMed ID: 8391387 [TBL] [Abstract][Full Text] [Related]
39. [Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients]. Zhou Q; Liang LJ; Peng BG; Zhen YY Ai Zheng; 2006 Nov; 25(11):1433-8. PubMed ID: 17094916 [TBL] [Abstract][Full Text] [Related]
40. Deflazacort modulates the fibrinolytic pattern and reduces uPA-dependent chemioinvasion and proliferation in rheumatoid arthritis synoviocytes. Del Rosso A; Cinelli M; Guiducci S; Pignone A; Fibbi G; Margheri F; Gabrielli A; Giacomelli R; Coppini A; Del Rosso M; Matucci Cerinic M Rheumatology (Oxford); 2005 Oct; 44(10):1255-62. PubMed ID: 15998634 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]